Drugs / QUAIL-100
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07573111 | Jun 2026 → Jun 2028 expected | acute leukemia, myelodysplastic syndrome | Laguna Biotherapeutics, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QUAIL-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07573111 ↗ |
| Modality | Other / unclassified | “live, attenuated bacterial therapeutic” NCT07573111 ↗ |